Committee processes evaluate safety efficacy (6 Ergebnisse)
- Softcover
Anbieter: Books From California, Simi Valley, CA, USABooks From California
Verkäufer/-in kontaktierenVerkäufer/-in mit 4 SternenZustand: Gebraucht - Sehr gut
EUR 27,04
EUR 4,37 VersandVersand innerhalb von USAAnzahl: 3 verfügbar
paperback. Zustand: Fine.
- Softcover
Anbieter: Books From California, Simi Valley, CA, USABooks From California
Verkäufer/-in kontaktierenVerkäufer/-in mit 4 SternenZustand: Gebraucht - Gut
EUR 31,22
EUR 4,37 VersandVersand innerhalb von USAAnzahl: 1 verfügbar
paperback. Zustand: Very Good.
Regulatory Processes for Rare Disease Drugs in the United States and European Union
National Academies Of Sciences, Engineering, And Medicine; Health And Medicine Division; Board On Health Sciences Policy; Committee On Processes To Evaluate The Safety And Efficacy Of Drugs For Rare Diseases Or Conditions In The United States And The European Union
- Softcover
Anbieter: PBShop.store US, Wood Dale, IL, USAPBShop.store US
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 43,81
Versand nach gratisVersand innerhalb von USAAnzahl: 1 verfügbar
PAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000.
Regulatory Processes for Rare Disease Drugs in the United States and European Union
National Academies Of Sciences, Engineering, And Medicine; Health And Medicine Division; Board On Health Sciences Policy; Committee On Processes To Evaluate The Safety And Efficacy Of Drugs For Rare Diseases Or Conditions In The United States And The European Union
- Softcover
Anbieter: PBShop.store UK, Fairford, GLOS, Vereinigtes KönigreichPBShop.store UK
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 39,43
EUR 5,82 VersandVersand von Vereinigtes Königreich nach USAAnzahl: 1 verfügbar
PAP. Zustand: New. New Book. Shipped from UK. Established seller since 2000.
Regulatory Processes for Rare Disease Drugs in the United St
National Academies Of Sciences, Engineering, And Medicine; Health And Medicine Division; Board On Health Sciences Policy; Committee On Processes To Evaluate The Safety And Efficacy Of Drugs For Rare Diseases Or Conditions In The United States And The European Union
- Softcover
Anbieter: buchversandmimpf2000, Emtmannsberg, BAYE, Deutschlandbuchversandmimpf2000
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 52,00
EUR 60,00 VersandVersand von Deutschland nach USAAnzahl: 1 verfügbar
Taschenbuch. Zustand: Neu. Neuware -Rare diseases, such as sickle cell disease and thalassemia, affect up to 30 million people in the United States and at least 300 million across the globe. Congress called on the U.S. Food and Drug Administration (FDA) to sponsor a National Academies study on processes for evaluating the safety… and efficacy of drugs for rare diseases or conditions in the United States and the European Union. The resulting report provides recommendations for enhancing and promoting rare disease drug development by improving engagement with people affected by a rare disease, advancing regulatory science, and fostering collaboration between FDA and the European Medicines Agency.Libri GmbH, Europaallee 1, 36244 Bad Hersfeld.
Regulatory Processes for Rare Disease Drugs in the United St
National Academies Of Sciences, Engineering, And Medicine; Health And Medicine Division; Board On Health Sciences Policy; Committee On Processes To Evaluate The Safety And Efficacy Of Drugs For Rare Diseases Or Conditions In The United States And The European Union
- Softcover
Anbieter: Books-by-Floh, Paderborn, DeutschlandBooks-by-Floh
Verkäufer/-in kontaktierenVerkäufer/-in mit 4 SternenZustand: Neu
EUR 73,25
EUR 105,00 VersandVersand von Deutschland nach USAAnzahl: 1 verfügbar
Taschenbuch. Zustand: Neu. Neuware -Rare diseases, such as sickle cell disease and thalassemia, affect up to 30 million people in the United States and at least 300 million across the globe. Congress called on the U.S. Food and Drug Administration (FDA) to sponsor a National Academies study on processes for evaluating the safety… and efficacy of drugs for rare diseases or conditions in the United States and the European Union. The resulting report provides recommendations for enhancing and promoting rare disease drug development by improving engagement with people affected by a rare disease, advancing regulatory science, and fostering collaboration between FDA and the European Medicines Agency.
